Cargando…
A Randomized, Double‐Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease
BACKGROUND: Agents targeting the metabotropic glutamate receptor 4 have emerged as a potentially attractive new class of drugs for the treatment of Parkinson's disease (PD). OBJECTIVE: The objective of this study was to evaluate the efficacy and safety of foliglurax in reducing off time and dys...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303267/ https://www.ncbi.nlm.nih.gov/pubmed/35218231 http://dx.doi.org/10.1002/mds.28970 |